1. Introduction {#s0005}
===============

Cancer is one of the most common causes of death in Western countries including Denmark ([@bb0155]) and therefore represents a serious burden to society and challenge to the healthcare system. Early diagnosis and timely treatment are associated with better prognosis. Many countries have therefore introduced organised cancer screening programmes, e.g. cervical cancer screening ([CCS](#dt0035){ref-type="term"}) and breast cancer screening ([BCS](#dt0020){ref-type="term"}). Screening is associated with a reduced incidence and mortality of cervical cancer ([CC](#dt0025){ref-type="term"}) and in combination with improved treatment ([@bb0215]), screening has been shown to reduce mortality from breast cancer ([BC](#dt0015){ref-type="term"}) ([@bb0110]; [@bb0100]).

In Denmark, local screening for CC began in the 1960s, and was gradually rolled out nationally ([@bb0140]), whereas BCS began locally in the 1990s and was implemented nationally in 2008 ([@bb0205]). High coverage is pivotal to achieving screening programme effectiveness; yet, far from all women participate in the programmes. In 2016, the participation rates were 64% for CCS and 82% for BCS in Denmark ([@bb0055]; [@bb0060]). Differences in participation in CCS and BCS may be due to age differences in the target groups, differences in the examination and sample collection, in invitations and in knowledge about the cancer types. Non-participation may be associated among others with linguistic or cultural barriers ([@bb0130]; [@bb0105]; [@bb0090]), psychosocial barriers ([@bb0090]; [@bb0120]), lack of resources ([@bb0130]; [@bb0105]; [@bb0090]; [@bb0120]) and fear of side effects ([@bb0080]).

Previous studies have reported an association between participation in CCS and BCS ([@bb0145]; [@bb0115]; [@bb0015]; [@bb0185]; [@bb0190]; [@bb0030]; [@bb0045]; [@bb0195]; [@bb0005]; [@bb0175]). However, these studies were based on self-selection and self-reported data in which overestimation of screening participation has been reported ([@bb0095]). To our knowledge, no studies have used solely register-based data to examine the association between non-participation in screening for CC and BC. Therefore, the aim of this study was to analyse the association between CCS coverage and participation in BCS.

2. Methods {#s0010}
==========

2.1. Setting and study design {#s0015}
-----------------------------

A historical register-based cohort study including women invited for the first organised screening round for BC was conducted.

In Denmark, screening programmes, as well as health care in general, are tax-funded and all residents have free access to health care ([@bb0150]). The first screening round for BC was implemented in the Central Denmark Region ([CDR](#dt0040){ref-type="term"}) during 2008--2009, where all women aged 50--69 years received an invitation with a specific, but changeable booking date for BCS ([@bb0205]). Non-participants received no reminders in the first screening round.

Screening for CC has been offered nationally every third year to all Danish women aged 23--59 years since 2006. From 2007 onwards, the screening interval was extended to include women aged 23--64 years, and for 50--64-year-old women the screening interval was changed from every third to every fifth year ([@bb0050]). Prior to 2006, screening was organised by 16 counties in Denmark, which caused small variations in the organisation of screening. However, 23--59-year-old women living in the current CDR have been offered BCS since 1996. CCS is performed by a general practitioner ([GP](#dt0060){ref-type="term"}) or a gynaecologist who obtain cervical smears for analysis. Smears are also used in cases where women are followed up for previous cervical intraepithelial neoplasia. Women are invited for screening by postal mail if they have not had a smear in the preceding 3 or 5 years (depending on age), and they must subsequently book an appointment with their GP to participate in the programme. In case of absence, reminders are sent to the woman, the first after 3 months, the second after 6 months.

All persons living in Denmark have a unique 10-digit identification number, called the civil personal registration number ([CPR](#dt0050){ref-type="term"}). This number is registered at every contact with public authorities, including the healthcare system ([@bb0170]), and the CPR enables linkage of register data at the level of the individual.

2.2. Study population {#s0020}
---------------------

The study cohort consisted of all women aged ≤ 64 years invited to the first screening round for BC in the CDR in 2008--2009 (*n* = 113,093). Excluded were women ([Fig. 1](#f0005){ref-type="fig"}) who had died (*n* = 110) or moved away from the CDR (*n* = 123) between receiving the invitation for BCS and the booking date, women who had lived outside of Denmark for 5 1/2 years prior to the booking date for BCS (*n* = 836), and women who were registered with a GP outside of the CDR (*n* = 91). We also excluded women if they were registered with a previous history of BC (*n* = 4646) (registered with ICD-10 code C50 in the Danish Cancer Register ([DCR](#dt0055){ref-type="term"}) ([@bb0075])) or gynaecological cancer (*n* = 1196) (registered with ICD-codes C51-C58 in the DCR). Furthermore, women registered with previous cervical conisation (*n* = 2826) were excluded (procedure codes: KLDC00 and KLDC03 in the National Patient Register ([NPR](#dt0075){ref-type="term"}) ([@bb0135]) or SnoMed-code: T83701 in the National Pathology Data Bank ([NPDB](#dt0070){ref-type="term"}) ([@bb0025])). Finally, we excluded women who were registered with previous total hysterectomy (n = 11,478), identified using the procedure codes in the NPR: KLCD00, KLCD01, KLCD04, KLCD10, KLCD11, KLCD30, KLCD31, KLCD40, KLCD96, KLCD97, KLDC13, KLDC20, KLDC23, KLEF00B, KLEF13 and KMCA33, or SnoMed-codes in the NPDB: T81900, T82000, T82900, T82920 and ÆAA030.Fig. 1Study flowchart for women invited to the first round of breast cancer screening (BCS) in the Central Denmark Region (CDR) in 2008--2009 within the relevant age group for cervical cancer screening (CCS).Fig. 1

In total, the study included 91,787 (81.2%) women invited to the first organised round of BCS within the relevant age group for CCS in the CDR.

2.3. Data collection and variables {#s0025}
----------------------------------

The main outcome was participation in the first BCS round in the CDR. Data on participation in the BCS were collected from an administrative database. Women were divided into participants and non-participants in BCS. As previously described by Jensen et al. ([@bb0105]), non-participants were subdivided into *active non*-*participants* ([ANP](#dt0005){ref-type="term"}) who cancelled their appointment and *passive non*-*participants* ([PNP](#dt0080){ref-type="term"}) who did not show up on the booking date.

CCS coverage was defined as having a minimum of one smear registered in the NPDB in the preceding 5 1/2 years before the BCS booking date. Women with a smear registered prior to this time or no smear at all were defined as not covered by CCS. The NPDB has existed since 1999 and every pathological specimen taken in Denmark is registered in the NPDB ([@bb0025]). The time interval of 5 1/2 years was chosen to ensure that all women, including those entitled to screening every five years, had received at least one CCS invitation and reminders if relevant during the study period.

Information on confounders was obtained from Statistics Denmark. *Age* was included as a continuous variable. *Educational* level was categorised according to the UNESCO classification ([@bb0200]) as 'low' (≤10 years), 'intermediate' (11--15 years) and 'high' (\>15 years). *Ethnicity* was categorised as 'Danish/descendants' and 'immigrants'; and *marital status* into 'married', 'cohabiting' and 'living alone'. *Income* was defined based on the OECD-adjusted household income ([@bb0165]), and based on tertiles categorised as 'low', 'intermediate' and 'high'. The Charlson Comorbidity Index ([CCI](#dt0030){ref-type="term"}) ([@bb0180]) (excluding breast and gynaecological cancer) was defined based on registration of the included diseases from hospital contacts in the NPR prior to the scheduled screening date, and the women were divided into a comorbidity score of '0', '1' and '≥2'.

2.4. Statistical analysis {#s0030}
-------------------------

The association between CCS coverage and BCS participation was estimated using generalised linear models with log link and the Bernoulli family regression models ([@bb0220]; [@bb0020]). We used prevalence rate ratios ([PRR](#dt0085){ref-type="term"}) with 95% confidence intervals ([CI](#dt0045){ref-type="term"}) and applied robust variance estimates to adjust for clustering of patients by general practice in both the unadjusted and adjusted models ([@bb0065]). The same analyses were applied to measure ANP and PNP in BCS as binary outcomes. Using stratified analyses, ANP were compared to participants in BCS (omitting PNP in these analyses), and subsequently PNP were compared to participants in BCS (omitting ANP in these analyses). All statistical analyses were conducted using STATA version 14.

2.5. Ethics {#s0035}
-----------

Since the study was based on data from registers only, no ethical approval was required according to Danish legislation and the National Committee on Health Research Ethics in the CDR (j. no. 181/2011). Approval for obtaining screening data was granted by the CDR\'s legal department and the Danish Data Protection Agency (j. no.: 1-16-02-109-09, j. no.: 1-16-02-376-16 and j. no.: 2009-41-3471).

3. Results {#s0040}
==========

3.1. Participation {#s0045}
------------------

Among the 91,787 women included, 21.5% were not covered by CCS and 20.2% were non-participants in BCS. In total, 68.0% (*n* = 62,391) were covered both by CCS and participated in BCS, and 9.7% (*n* = 8877) were neither covered by CCS nor participated in BCS ([Fig. 2](#f0010){ref-type="fig"}). Of the women covered by CCS, 13.4% (*n* = 9672) did not participate in BCS, and of the women who participated in BCS, 14.8% (*n* = 10,847) were not covered by CCS ([Table 1](#t0005){ref-type="table"}).Fig. 2Distribution of cervical cancer screening (CCS) coverage and breast cancer screening (BCS) participation among 91,787 (100%) women invited to BCS in the Central Denmark Region (CDR) in 2008--2009.Fig. 2Table 1Distribution of cervical cancer screening (CCS) non-coverage, socio-demography and Charlson\'s comorbidity index (CCI) among participants (*n* = 73,238), non-participants (*n* = 18,549) and non-participants divided into active (ANP) (*n* = 8314) vs. passive (PNP) (*n* = 10,235) non-participants in breast cancer screening (BCS).Table 1VariableParticipants in BCS[a](#tf0005){ref-type="table-fn"}Non-participants in BCS*P*-value\
(chi^2^)ANP in BCSPNP in BCSP-value\
(chi^2^)n(%)n(%)n(%)n(%)All women73,238(79.8)18,549(20.2)8314(44.8)10,235(55.2)CCS coverage[b](#tf0010){ref-type="table-fn"}\<0.001\<0.001 No smear10,847(55.0)8877(45.0)3214(36.2)5663(63.8) Smear62,391(86.6)9672(13.4)5100(52.7)4572(47.3)Age (years)0.002\<0.001 50--5425,691(80.2)6393(19.8)2567(40.2)3826(59.9) 55--5925,988(79.9)6531(20.1)2879(44.1)3652(55.9) 60--6421,289(79.1)5625(20.9)2868(51.0)2757(49.0)Ethnicity\<0.001\<0.001 Danish/descendant70,661(80.5)17,146(19.5)8001(46.7)9145(53.3) Immigrant2577(64.8)1403(35.3)313(22.3)1090(77.7)Marital status\<0.001\<0.001 Married52,761(84.1)9974(15.9)5061(50.7)4913(49.3) Cohabiting5500(77.7)1578(22.3)569(36.1)1009(63.9) Living alone14,977(68.2)6997(31.8)2684(38.4)4313(61.6)OECD-adjusted household income\<0.001\<0.001 Low14,870(67.6)7139(32.4)2568(36.0)4571(64.0) Intermediate26,677(81.4)6116(18.7)2857(46.7)3259(53.3) High31,691(85.7)5294(14.3)2889(54.6)2405(45.4)Educational level\<0.001\<0.001 Low22,396(76.5)6876(23.5)2676(38.9)4200(61.1) Intermediate31,714(82.4)6766(17.6)3314(49.0)3452(51.0) High18,354(80.4)4479(19.6)2206(49.3)2273(50.8)Charlson Comorbidity Index\<0.001\<0.001 051,588(82.1)11,279(17.9)5099(45.2)6180(54.8) 16637(77,2)1961(22.8)781(39.8)1180(60.2) ≥23600(71.2)1455(28.8)656(45.1)799(54.9)[^1][^2][^3]

3.2. Sociodemographic characteristics {#s0050}
-------------------------------------

A higher proportion of BCS non-participants was found among older women (60--64 years), immigrants, women living alone, women with low income, low educational level and a CCI ≥ 2 than among BCS participants ([Table 1](#t0005){ref-type="table"}). A higher proportion of PNP was found among younger women (50--54 years), immigrants, non-married women, women with low income and low educational level, and women with a CCI of 1 (but not CCI ≥ 2) than among women who were ANP ([Table 1](#t0005){ref-type="table"}).

3.3. Association between BCS participation and CCS coverage {#s0055}
-----------------------------------------------------------

The association between CCS coverage and BCS participation is presented in [Table 2](#t0010){ref-type="table"}. In the adjusted analysis, women not covered by CCS were nearly three times more likely to be BCS non-participants than women covered by CCS (PRR~adjusted~ = 2.80, 95% CI: 2.68--2.93).Table 2The association (prevalence rate ratio (PRR)) between being covered by cervical cancer screening (CCS) and being non-participant in breast cancer screening (BCS), passive (PNP) or active (ANP) non-participant in BCS compared to being BCS participant.Table 2Non-participation in BCS[a](#tf0015){ref-type="table-fn"}PNP in BCS[b](#tf0020){ref-type="table-fn"}ANP in BCS[c](#tf0025){ref-type="table-fn"}Unadjusted PRR\
(95% CI)Adjusted[d](#tf0030){ref-type="table-fn"} PRR\
(95% CI)Unadjusted PRR\
(95% CI)Adjusted[d](#tf0030){ref-type="table-fn"} PRR\
(95% CI)Unadjusted PRR\
(95% CI)Adjusted[d](#tf0030){ref-type="table-fn"} PRR\
(95% CI)CCS coverage[e](#tf0035){ref-type="table-fn"}Smear1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)No smear**3.35**\
**(3.22--3.50)2.80**\
**(2.68--2.93)5.02**\
**(4.80--5.26)3.99**\
**(3.80--4.19)3.02**\
**(2.85--3.21)2.50**\
**(2.34--2.68)**[^4][^5][^6][^7][^8][^9]

Women not covered by CCS were four times more likely to be PNP (PRR~adusted~ = 3.99 (95% CI: 3.80--4.19), whereas they were 2.5 times more likely to be ANP (PRR~adjusted~ = 2.50, 95% CI: 2.34--2.68) than women covered by CCS ([Table 2](#t0010){ref-type="table"}).

4. Discussion {#s0060}
=============

4.1. Main findings {#s0065}
------------------

This historical register-based cohort study found that CCS non-coverage was strongly associated with later BCS non-participation. Women who were not covered by CCS had a three-time larger likelihood of not participating in a later BCS than women covered by CCS. Of all women included in the study, one in ten was neither covered by CCS nor participated in BCS, and two thirds were both covered by CCS and participated in BCS.

4.2. Study limitations and strengths {#s0070}
------------------------------------

A major strength of this study was that all information was retrieved from Danish registers, which are known to be valid and complete ([@bb0075]; [@bb0135]; [@bb0025]). This minimised information bias and ensured that we had accurate information on possible confounders at the level of the individual. Furthermore, since precise inclusion and restriction was possible, selection bias was minimised. Hence, the generalisability of the study is high, and the findings are thus applicable to other countries with similar screening programmes.

However, certain weaknesses should also be acknowledged. Firstly, women aged 60--64-year old were included in the CCS after 2007, yet the exact implementation date is not documented and differ across Denmark, thus it cannot be ruled out that some of the oldest women were not invited as intended to the CCS which may result in an underestimation of CCS coverage. However, this will not be associated with participation on BCS and will therefore not affect the association under study. Secondly, data on previous hysterectomy in the NPR and the NPDB were not available prior to 1977 and 1999, respectively ([@bb0135]; [@bb0025]). Thus, women with a hysterectomy or conisation who were 24 years or younger in 1977 were misclassified. Since hysterectomies are rare in young Danish women ([@bb0125]), this is of minor importance in the present study. Previous studies have found several factors that could be associated with both CCS and BCS screening participation but remain unadjusted for in this study, such as BMI ([@bb0040]), urbanity ([@bb0130]; [@bb0105]) and smoking ([@bb0090]; [@bb0120]). Hence, residual confounding cannot be ruled out. Furthermore, this study does not indicate whether the link between CCS coverage and BCS participation is causal although this study, as one of the first in the fields, offers a temporal separation of CCS coverage following assessment of BCS participation. Future studies should investigate further in details the mechanism affecting non-participation across screening programmes.

4.3. Comparison with other studies {#s0075}
----------------------------------

The results of this study are consistent with the results of previous international studies ([@bb0145]; [@bb0115]; [@bb0015]; [@bb0185]; [@bb0190]; [@bb0030]; [@bb0045]; [@bb0195]; [@bb0005]; [@bb0175]), which also found an association between CCS and BCS participation, even though these previous studies were non-comparable in various ways. Different age groups were included and definitions of CCS and BCS participation varied among the studies from 'ever being screened' ([@bb0175]) to 'being screened within the previous year' ([@bb0045]). Moreover, previous studies were all mainly based on self-reported data and thus likely to be biased due to participation overestimation ([@bb0095]) and self-selection.

Screening behaviour is most likely determined by a complex range of persistent underlying factors, for example that the woman abstains from screening because she anticipates discomfort during examination and fears pain ([@bb0070]; [@bb0010]; [@bb0210]) or embarrassment ([@bb0080]; [@bb0070]; [@bb0010]; [@bb0210]). Women may also be afraid of the result of the screening ([@bb0080]; [@bb0010]; [@bb0210]) or may be convicted that it is better not to know ([@bb0080]; [@bb0010]). Other factors may be associated with absence of knowledge or simple misconceptions about cancer and screening, such as thinking that screening is unnecessary if there are no symptoms or believing that cancer will not strike ([@bb0080]; [@bb0070]; [@bb0210]). Busyness may also be a barrier ([@bb0120]; [@bb0070]; [@bb0210]), and some simply do not attend for no specific reason ([@bb0210]). Moreover, the decision to participate in one type of screening may influence the decision to participate in another type of screening, causing a spill-over effect as suggested by Labeit et al. ([@bb0115]). Finally, recent media focus on the negative side effects of screening, such as over-diagnosis and false positives/negatives, may also contribute to non-participation. In Denmark, focus has particularly been on BCS over-diagnosis, although the extent of overdiagnosis is heavily debated ([@bb0085]; [@bb0160]). Thus, concern about over-diagnosis could explain why some women participate only in CCS, however, it is unlikely to explain the association between CCS and BCS participation.

The present study revealed that CCS non-coverage was more strongly associated with passive non-participation than with active non-participation in BCS. To our knowledge, two other studies ([@bb0105]; [@bb0010]) have studied subgroups of non-participants in BCS, and none of these evaluated the relation to CCS coverage. To improve screening uptake, efforts should be targeted at PNP in particular because their decision may not have been informed and their participation could possibly be barred by factors that could be addressed in interventions. Thus, additional research is needed to further understand this association.

4.4. Implications {#s0080}
-----------------

Non-participation in screening is an individual decision. However, research into reasons for non-participation and into how screening programmes may be improved is essential to ensure that access is truly equal and to achieve optimal societal effect of screening. Thus, the present study shows that women not covered by CCS are more likely to be BCS non-participants. This knowledge is important for GPs, who should be observant of women who do not participate in either CCS or BCS, since they are more likely also to be non-participants in the other screening programme. Furthermore, by addressing possible underlying factors related to non-participation, doctors may possibly be able to help address relevant participation barriers.

We showed that non-participation in CCS was more pronounced among PNP than among ANP in BCS. As noted above, these women may not have made an informed decision about non-participation. Thus, more information from doctors, health authorities and in the media could provide these women with information needed to make a decision about screening participation.

For women only participating in one screening offer, healthcare personnel may engage in conversation with the woman about participation in CCS when the woman attends BCS and vice versa. This conversation could also take place when a woman with no recent CCS participation calls to cancel her appointment for BCS.

Another possibility worth exploring is to introduce 'integrated screening sites' where women are invited to participate in more than one screening at the same time. This would likely increase participation ([@bb0035]). Women who do not participate in any of the screening programmes might also benefit from such an intervention since screening would become more accessible and less time-consuming. On the other hand, some women may find it overwhelming to attend two screenings on the same day. Furthermore, recommended screening intervals vary between CCS and BCS, which should also be taken into consideration.

5. Conclusion {#s0085}
=============

This historical register-based cohort study shows that previous CCS behaviour was strongly associated with later BCS behaviour. However, the study also identified groups of women participating in only one type of screening. To raise participation, future interventions may target these groups, e.g. by establishing integrated screening sites.
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[^1]: Numbers vary due to missing data.

[^2]: Defined as participation in the first round of breast cancer screening (BCS) in the Central Denmark Region (CDR) in 2008--2009.

[^3]: Defined as having a smear registered in the National Pathology Data Bank (NPDB) in the 5 1/2 years preceding the booking date for breast cancer screening (BCS).

[^4]: Significant values are in bold\" (as all results are significant, all estimates are in bold).

[^5]: Defined as non-participation in the first round of breast cancer screening (BCS) in the Central Denmark Region (CDR) in 2008--2009.

[^6]: Stratified analyses, comparing PNP to BCS participants omitting ANP\'s.

[^7]: Stratified analyses comparing ANP to BCS participants omitting PNP\'s.

[^8]: Adjusted for age, ethnicity, marital status, OECD-adjusted household income, educational level and Charlson comorbidity index score.

[^9]: Defined as having a smear registered in the National Pathology Data Bank (NPDB) in the 5 1/2 years preceding the booking date for breast cancer screening (BCS).
